Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MNOV vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNOV Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–3 Matrix Metrics)

MNOV Overall Winner 6-Pillar Tally: MNOV 5 – 0 CLYM (1 Tie) Matrix Metrics: MNOV 6 – 3 CLYM

As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas CLYM carries 43.7/100 (HOLD) at $9.19 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNOV vs CLYM
MNOV NASDAQ Head-to-Head Winner
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 106% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.4%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $10.04 · SMA50: $11.01

6-Pillar Scorecard Institutional Category Breakdown (MNOV 5 – 0 CLYM)

Columns: Metric · MNOV · CLYM
1. Valuation Multiples MNOV
Forward P/E 8.5x N/M
Trailing P/E 8.5x N/M
PEG Ratio N/M N/M
EV / Revenue 42.5x N/M
2. Growth & Scale MNOV
Revenue Growth (YoY) +12.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $935,717 N/A
Market Cap $65.1M $545.1M
3. Profitability & Quality MNOV
Gross Margin 42.2% N/A
Operating Margin -1232.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -24.8% -29.3%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$9.1M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $25M Net Cash $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNOV
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 140.1% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNOV (6) vs CLYM (3)
Institutional Metric MNOV CLYM Criterion Row Edge
Market Capitalization
Scale
$65.1M $545.1M Larger Scale CLYM
Trailing P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+12.4% +0.0% Higher Growth MNOV
Operating Margin (TTM)
Profitability
-1232.2% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-24.8% -29.3% Higher ROE MNOV
52-Week Range Position
Momentum
3% ($1–$4) 45% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
0.59β · 38% Vol 1.42β · 106% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$935,717 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 42.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($25M Net Cash) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNOV +5.72 pp
MNOV: -7.09% · CLYM: -12.81%
3M Horizon MNOV +29.58 pp
MNOV: -14.38% · CLYM: -43.96%
6M Horizon MNOV +10.02 pp
MNOV: -6.43% · CLYM: -16.45%
1Y Horizon CLYM +407.85 pp
MNOV: -8.39% · CLYM: +399.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNOV vs CLYM. Trailing 12-month operating profitability (MNOV -1232.2% vs CLYM 0.0%) and valuation multiples (MNOV 8.5x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MNOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$935,717
Gross Margin42.2%
Op. Margin-1232.2%
ROE / Fwd P/E-24.8% · 8.5x
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $545.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNOV vs CLYM Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicinova, Inc. (MNOV) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas CLYM carries 43.7/100 (HOLD) at $9.19 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MNOV leads the Growth & Scale pillar: MNOV posts +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MNOV generates $935,717 in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, MNOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

MNOV screens cheaper on headline valuation multiples. MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNOV (-24.8% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.